Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.

Shadi EsmaeiliAmir-Mohammad YousefiMahda DelshadSoroush Sadeghi

Published in: Molecular genetics & genomic medicine (2022)

This study sheds light on the significance of the PI3K/Akt pathway in APL cell sensitivity to pioglitazone and proposed that the presence of the PI3K inhibitor in the therapeutic regimen containing pioglitazone could be promising in the treatment of this malignancy.

Keyphrases

induced apoptosis
liver failure
cell cycle arrest
acute myeloid leukemia
bone marrow
cell therapy
drug induced
combination therapy
cell death
aortic dissection
mesenchymal stem cells
acute respiratory distress syndrome
mechanical ventilation